The market for motion sickness might appear to be saturated by well-known and convenient products such oral Dramamine and Bonine and patches. But on the heels of positive Phase III data for its intranasal scopolamine, Nastech Pharmaceutical Co. Inc. believes that the side effect profile and rapid onset of its product could offer an attractive alternative.

The company anticipates filing an NDA in the fourth quarter for both treatment and prevention of motion sickness.